FDA Approves New Chorea Treatment
The FDA announced Aug. 15 that it has approved Prestwick Pharmaceuticals Inc.’s new drug Xenazine (generic name tetrabenazine) for the treatment of chorea in people with Huntington’s disease, heralding the first treatment to receive U.S. approval for any of the disease’s symptoms (Medical News Today, Aug. 18).
Chorea, once called St. Vitus’ Dance, is characterized by brief, irregular contractions that appear to flow from one muscle to the next. This neurological feature is a primary symptom of Huntington’s disease but can be caused by drugs, metabolic disorders, endocrine disorders, and vascular incidents.
Latest posts by admin aapc (see all)
- US gets the ball rolling on ICD-11 - August 16, 2019
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018